

A


Effector Donor 1
% Specific Lysis
100
50
0
0.0001
0.001
0.01
0.1
1
10
100
αFGFR2b (μg/ml)
αFGFR2bF / FGFR2b
αFGFR2bA / FGFR2b
αFGFR2b / FGFR2c

B


Effector Donor 2
% Specific Lysis
100
50
0
0.00001
0.0001
0.001
0.01
0.1
1
10
100
αFGFR2b (μg/ml)
αFGFR2bF / FGFR2b
αFGFR2bA / FGFR2b

C



Effector Donor 3
% Specific Lysis
100
50
0
0.00001
0.0001
0.001
0.01
0.1
1
10
100
αFGFR2b (μg/ml)
αFGFR2bF / FGFR2b
αFGFR2bA / FGFR2b

FIG. 1



A
OCUM2M 10mg/kg
Albumin 10 mg/kg
anti-FGFR2bA 10 mg/kg
anti-FGFR2bF 10 mg/kg
Tumor Volume (Mean mm3±SEM)
Days post inoculation
B
p=0.0153
Tumor Volume (mm3)
anti-FGFR2bA 10 mg/kg
anti-FGFR2bF 10 mg/kg
C
OCUM2M 3mg/kg
Albumin 10mpk
anti-FGFR2bA 3 mg/kg
anti-FGFR2bF 3 mg/kg
Tumor Volume (Mean mm3±SEM)
Days post inoculation
D
p=0.0767
Tumor Volume (mm3)
anti-FGFR2bA 3 mg/kg
anti-FGFR2bF 3 mg/kg

FIG. 2



A
OCUM2M
Tumor Volumes
Albumin
anti-FGFR2bA 1 mg/kg
anti-FGFR2bA 1.5 mg/kg
anti-FGFR2bA 2 mg/kg
anti-FGFR2bA 3 mg/kg
anti-FGFR2bA 5 mg/kg
Tumor Volume
(Mean mm3 ±SEM)
Days Post Tumor Implantation
B
Day 49
Tumor Volume
(mm3)
Albumin
anti-FGFR2bA (mg/kg)

FIG. 3



A
OCUM-2Mv1
Tumors Volumes
Albumin/Vehicle
Paclitaxel/Albumin
anti-FGFR2bA/Vehicle
anti-FGFR2bA/Paclitaxel
Tumor Volume
(Mean mm3±SEM)
Post Tumor Implantation
B
Day 63
p=0.0009
p=0.0005
Tumor Volume
(mm3)
Alb/Vehicle
a-FGFR2bA
Paclitaxel
a-R2bA/PTX

FIG. 4



A
OCUM-2Mv1
Tumors Volumes
Albumin
anti-FGFR2bA/Vehicle
5FU/Cisplatin/Albumin
anti-FGFR2bA/5FU/Cis
Tumor Volume
(Mean mm3±SEM)
1200
1000
800
600
400
200
0
10
20
30
40
Days Post Tumor Implantation
B
Day 38
Tumor volume
(mm3)
2000
1500
1000
500
0
p=0.0003
Albumin
a-FGFR2bA
5FU/Cis
aR2bA/5FU/Cis

FIG. 5



A
MFM-223
Tumor volume
Albumin 5 mg/kg
anti-FGFR2bA 5 mg/kg
Tumor Volume
(Mean mm³±SEM)
300
200
100
0
20
30
40
50
60
70
80
90
Days Post Tumor Implantation
B
Day 87
p=0.0008
Tumor volume
(mm³)
500
400
300
200
100
0
Albumin
anti-FGFR2bA

FIG. 6




A
G0
12.576
G0GlcN
11.264
Man-5
14.497
G1
14.762
B
G0F
12.510
G0
G0FGlc
12.566
12.264
Man-5
14.396
G1F
15.396
G1F'
15.656
G2F
17.461

FIG. 7



Mannose-5 (Man-5)

FIG. 8



Ba/F3 FGFR2b ADCC: Donor 9
LDH absorbance
4
3
2
1
0
-8
-6
-4
-2
0
2
log [FI
log [αFGFR2b] (μg/ml)
αFGFR2bA
αFGFR2bF

FIG. 9



OCUM-2M ADCC: Donor 9
% Specific Lysis
60
40
20
0
-8
-6
-4
-2
0
2
log [αFGFR2b] (μg/ml)
αFGFR2bA
αFGFR2bF

FIG. 10




FIG. 11